• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Ischemic Stroke with Cancer: Hematologic and Embolic Biomarkers and Clinical Outcomes
CONCLUSIONS: Markers of hypercoagulability and embolic disease may be associated with adverse clinical outcomes in cancer-related stroke.PMID:35652416 | DOI:10.1111/jth.15779
Source: Thrombosis and Haemostasis - June 2, 2022 Category: Hematology Authors: Babak B Navi Cenai Zhang Carla P Sherman Richard Genova Natalie M LeMoss Hooman Kamel Scott T Tagawa Ashish Saxena Allyson J Ocean Scott E Kasner Mary Cushman Mitchell S V Elkind Ellinor Peerschke Lisa M DeAngelis Source Type: research

Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy
cancer and cerebrovascular disease are among the most common causes of death in the developed countries and are both associated with a steep increase in incidence among the elderly population. Despite being a less frequent neurological complication in cancer patients, compared to metastases or neurotoxicity from anticancer treatment, stroke incidence in cancer patients is high [1]. The pathophysiology of stroke in cancer patients is largely unknown [2] and can be attributed to cardiac or non-cardiac embolism.
Source: Thrombosis Research - June 18, 2015 Category: Hematology Authors: Gentian Denas, Vittorio Pengo, Roberta Joppi, Paolo Prandoni Source Type: research

Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism
Direct oral anticoagulants (DOACs) are at least as efficacious as conventional anticoagulation therapy for the initial and long-term treatment of cancer patients with venous thromboembolism (VTE). Whether DOACs are non-inferior to low-molecular-weight heparin for the management of cancer patients with VTE is under investigation. In addition, the efficacy of DOACs for the treatment of cancer patients with arterial thrombosis (e.g., ischemic stroke) remains unclear. Herein, we report on two cancer patients admitted to our hospital with Stage IV gastric adenocarcinoma who were being treated with DOACs due to a history of VTE ...
Source: Thrombosis Research - March 31, 2017 Category: Hematology Authors: Yasufumi Gon, Manabu Sakaguchi, Junji Takasugi, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research

Cancer, atrial fibrillation, and stroke
Cancer patients appear to be at increased risk for atrial fibrillation. Although surgery and chemotherapy exacerbate this risk, this association is observed even in the absence of any cancer-specific treatment. The underlying mechanism of this is likely multifactorial, but systemic inflammation and autonomic dysregulation are hypothesized to play critical roles. Cancer and atrial fibrillation are both independent risk factors for ischemic stroke; however, it is not clear whether this translates to an increased risk of stroke in patients with both comorbidities.
Source: Thrombosis Research - May 9, 2017 Category: Hematology Authors: Tess Sudenis, Marc Carrier, Gr égoire Le Gal Tags: Review Article Source Type: research

Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism
Anticoagulation therapy, especially using heparin or recently developed oral direct factor Xa inhibitors (DiXals), is recommended as first-line treatment for cancer-related venous thromboembolism (VTE). However, the preventive efficacy of these anticoagulants for cancer-associated ischemic stroke is still unknown. We retrospectively investigated the efficacy of subcutaneous unfractionated heparin (UFH) and DiXals for preventing the recurrence of cancer-associated cryptogenic ischemic stroke with VTE.
Source: Thrombosis Research - August 23, 2021 Category: Hematology Authors: Genpei Yamaura, Takeshi Ito, Yosuke Miyaji, Naohisa Ueda, Yoshiharu Nakae, Takayuki Momoo, Tatsu Nakano, Yuji Johmura, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Hideyuki Takeuchi, Tatsuya Takahashi, Shigeru Koyano, Shigeki Yamaguchi, Mutsumi Yokoyama, Source Type: research

Stroke mortality in cancer survivors: A population-based study in Japan
The association between cancer survivors and stroke deaths remains unclear. We aimed to evaluate the risk of fatal stroke in patients with cancer.
Source: Thrombosis Research - January 9, 2023 Category: Hematology Authors: Yasufumi Gon, Ling Zha, Tsutomu Sasaki, Toshitaka Morishima, Yuko Ohno, Hideki Mochizuki, Tomotaka Sobue, Isao Miyashiro Source Type: research

NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation
Large elevations of high sensitive Troponin T (hsTnT) in ischemic stroke patients is associated with a poor outcome. In a pilot study we found a high prevalence of malignancies among these patients. Since neutrophil extracellular traps (NETs) have been linked to cancer-associated thrombosis, we hypothesized that the concomitant cerebral and myocardial ischemia could be the result of a NET-induced hypercoagulable state.
Source: Thrombosis Research - January 12, 2016 Category: Hematology Authors: Charlotte Thålin, Melanie Demers, Bo Blomgren, Siu Ling Wong, Magnus von Arbin, Anders von Heijne, Ann Charlotte Laska, Håkan Wallén, Denisa D. Wagner, Sara Aspberg Tags: Full Length Article Source Type: research

Cancer, other comorbidity, and risk of venous thromboembolism after stroke: a population-based cohort study
The impact of cancer and other comorbidity on the risk of venous thromboembolism (VTE) after stroke is poorly understood.
Source: Thrombosis Research - September 28, 2016 Category: Hematology Authors: Priscila Corraini, Anne Gulbech Ording, Victor W. Henderson, Szimonetta Sz épligeti, Erzsébet Horváth-Puhó, Henrik Toft Sørensen Tags: Original Article Source Type: research

Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study.
In conclusion, elevated platelet count is associated with higher mortality and risk of CV events, regardless of previous MI and stroke. Platelet count may thus be a useful marker for further stratification of CV risk, and especially of death. PMID: 31430798 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 19, 2019 Category: Hematology Authors: Patti G, Di Martino G, Ricci F, Renda G, Gallina S, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A Tags: Thromb Haemost Source Type: research

Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION:  In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients. PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Thromboembolism and bleeding in patients with cancer and mechanical heart valves
AbstractMechanical heart valves (MHV) require life-long anticoagulation with vitamin K antagonists (VKA), but anticoagulation management is complex in patients with cancer due to a high risk of thrombosis and bleeding. This is a retrospective, single-center study to assess anticoagulation management and thrombotic (stroke/valve thrombosis) and bleeding events in patients with active cancer and MHV. The incidence of thrombotic complications was compared to a control group (matched 1:1) of patients with MHV but without cancer. We included 48 patients, 60% of whom had aortic prostheses, 23% mitral prostheses and 17% both type...
Source: Journal of Thrombosis and Thrombolysis - December 17, 2018 Category: Hematology Source Type: research

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
ConclusionsIn comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
Source: Journal of Thrombosis and Thrombolysis - October 12, 2020 Category: Hematology Source Type: research

Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research

Pages: 1  2  3  4  5  6  7